The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto–Kakizaki Rats
Author:
Affiliation:
1. Tsukuba Research Center, Drug Discovery Research, Astellas Pharma Inc.
Publisher
Pharmaceutical Society of Japan
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Link
https://www.jstage.jst.go.jp/article/bpb/40/5/40_b16-00964/_pdf
Reference40 articles.
1. 1) Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 29, 1130–1139 (2006).
2. 2) DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia, 53, 1270–1287 (2010).
3. 3) Palermo A, Maggi D, Maurizi AR, Pozzilli P, Buzzetti R. Prevention of type 2 diabetes mellitus: is it feasible? Diabetes Metab. Res. Rev., 30 (Suppl. 1), 4–12 (2014).
4. 4) Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med., 12, 123 (2014).
5. 5) Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR, Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care, 34, 1424–1430 (2011).
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet;Biomedicine & Pharmacotherapy;2024-05
2. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK);PLOS ONE;2021-05-04
3. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism;Heart Failure Reviews;2021-03-12
4. Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome;International Journal of Molecular Sciences;2021-03-04
5. Update on: effects of anti-diabetic drugs on bone metabolism;Expert Review of Endocrinology & Metabolism;2020-10-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3